Search

Your search keyword '"Peters, Klaus"' showing total 544 results

Search Constraints

Start Over You searched for: Author "Peters, Klaus" Remove constraint Author: "Peters, Klaus"
544 results on '"Peters, Klaus"'

Search Results

501. Wetting and reactive wetting during hot-dip galvanizing of high Mn alloyed steel with Zn–Al–Mg baths

502. Use of pre-oxidation to improve reactive wetting of high manganese alloyed steel during hot-dip galvanizing

503. Reactive wetting during hot-dip galvanizing of high manganese alloyed steel

504. Wetting force and contact angle measurements to evaluate the influence of zinc bath metallurgy on the galvanizability of high-manganese-alloyed steel

508. Relation of N-Terminal Pro-B-Type Natriuretic Peptide to Symptoms, Severity, and Left Ventricular Remodeling in Patients With Organic Mitral Regurgitation

511. Reducing Computational Load for Mixed Integer Linear Programming: An Example for a District and an Island Energy System.

512. Auswahl für oder durch den Kunden? Die Auswirkungen des Richtungsstreits auf Bestandsmanagement und Bestandsvermittlung in Öffentlichen Bibliotheken der Gegenwart

513. Protein contact dermatitis due to cow dander.

514. Pulmonary hypertension: Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011

515. LETTERS.

516. Use of an estradiol transdermal spray in women with menopausal symptoms: a non-interventional study.

517. [National Competence Network Contergan - Ensuring medical care for people with thalidomide embryopathy].

518. Health-related quality of life after 50 years in individuals with thalidomide embryopathy: Evidence from a German cross-sectional survey.

519. [Chronic Pain in People Impaired by Thalidomide Embryopathy: An Explorative Analysis of Prevalence, Pain Parameters and Biopsychosocial Factors].

520. Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone.

521. Correction: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone.

522. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.

523. [Upcoming challenges in providing care for thalidomide impaired individuals].

524. Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine.

525. [Update of the German S3 guideline on atraumatic femoral head necrosis in adults].

526. Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.

527. Mental Disorders in People Affected by Thalidomide.

528. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.

529. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.

530. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

531. Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.

532. Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

533. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study.

534. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.

535. Nexplanon, a radiopaque etonogestrel implant in combination with a next-generation applicator: 3-year results of a noncomparative multicenter trial.

536. Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota.

537. Diagnostics of autoimmune bullous diseases in German dermatology departments.

538. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

539. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study.

540. [Diagnosis and treatment of osteoporosis according to current guidelines].

541. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women.

542. The diagnosis and treatment of primary osteoporosis according to current guidelines.

544. Natural display mode for digital DICOM-conformant diagnostic imaging.

Catalog

Books, media, physical & digital resources